NCT06992999View on ClinicalTrials.gov

Psilocybin for Treatment of OCD-2

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Obsessive - Compulsive Disorder
Interventions
DRUG

Low Dose Psilocybin

10mg dose of psilocybin

DRUG

High Dose Psilocybin

30mg dose of psilocybin

Trial Locations (1)

85724

University of Arizona-Tucson, Tucson

All Listed Sponsors
collaborator

University of Arizona

OTHER

lead

Francisco A Moreno

OTHER

NCT06992999 - Psilocybin for Treatment of OCD-2 | Biotech Hunter | Biotech Hunter